会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • NK1 ANTAGONISTS
    • NK1拮抗剂
    • WO2006089658A2
    • 2006-08-31
    • PCT/EP2006/001310
    • 2006-02-14
    • F. HOFFMANN-LA ROCHE AGHOFFMANN, TorstenSCHNIDER, Patrick
    • HOFFMANN, TorstenSCHNIDER, Patrick
    • C07D213/75A61K31/44A61P25/18
    • C07D213/75C07D213/82
    • The present invention relates to compounds of the formula (I), wherein R 1 /R 1’ are hydrogen or methyl; X is -C(O)N(CH 3 )- or -N(CH 3 )C(O)-; and to pharmaceutically acceptable acid addition salts thereof for the treatment of numerous inflammatory conditions, migraine, rheumatoid arthritis, asthma, inflammatory bowel disease, mediation of the emetic reflex, Parkinson's disease, anxiety, depression, psychosis, motion sickness, induced vomiting, pain, headache, migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, traumatic brain injury, motion sickness, emesis and psychoimmunologic or psychosomatic disorders.
    • 本发明涉及式(I)化合物,其中R 1,R 2,R 1,R 2, X是-C(O)N(CH 3) - 或-N(CH 3)C(O) - ; 以及其药学上可接受的酸加成盐,用于治疗许多炎性病症,偏头痛,类风湿性关节炎,哮喘,炎症性肠病,呕吐反射调节,帕金森病,焦虑症,抑郁症,精神病,运动病,诱导性呕吐,疼痛, 头痛,偏头痛,阿尔茨海默病,多发性硬化,吗啡戒断减轻,心血管改变,水肿,如热损伤引起的水肿,慢性炎性疾病如类风湿性关节炎,哮喘/支气管高反应性和其他呼吸系统疾病,包括过敏性鼻炎,炎性疾病 的肠道,包括溃疡性结肠炎和克罗恩病,眼部损伤和眼部炎症性疾病,创伤性脑损伤,运动病,呕吐和心理免疫或心身疾病。
    • 8. 发明申请
    • PYRROLIDINE DERIVATIVES AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS
    • 吡咯啉衍生物作为NK1 / NK3受体拮抗剂
    • WO2008128891A1
    • 2008-10-30
    • PCT/EP2008/054261
    • 2008-04-09
    • F. HOFFMANN-LA ROCHE AGBISSANTZ, CaterinaHOFFMANN, TorstenJABLONSKI, PhilippeKNUST, HennerNETTEKOVEN, MatthiasRATNI, HasaneWU, Xihan
    • BISSANTZ, CaterinaHOFFMANN, TorstenJABLONSKI, PhilippeKNUST, HennerNETTEKOVEN, MatthiasRATNI, HasaneWU, Xihan
    • C07D207/14C07D401/06C07D403/06C07D405/06C07D471/10A61K31/5377A61P25/28
    • C07D207/14C07D401/06C07D403/06C07D405/06C07D471/10
    • The invention relates to pyrrolidine derivatives of formula (I) wherein R 1 is hydrogen, halogen or lower alkyl; R 2 is hydrogen, halogen, lower alkoxy or lower alkyl substituted by halogen; R 3 is -(CH 2 ) p -heterocyclyl optionally substituted by lower alkyl, halogen, -S(O) 2 -lower alkyl, -C(O)-lower alkyl, -C(O)O-lower alkyl, hydroxy, lower alkyl substituted by hydroxy, -(CH 2 ) p -O-lower alkyl, -NHCO-lower alkyl, or is C 3-6 -cycloalkyl optionally substituted by =O, -(CH 2 ) p -O-lower alkyl or lower alkinyl, or is unsubstituted or substituted aryl or heteroaryl, wherein the substituents are selected from the group consisting of lower alkyl, CN, -S(O) 2 -lower alkyl, halogen, -C(O) -lower alkyl, hydroxy, lower alkoxy or lower alkoxy substituted by halogen; or is -(CH 2 ) P -NR 4 R 5 ; R 4 /R 5 are independently from each other hydrogen, lower alkyl, -(CRR')p-lower alkyl substituted by hydroxy, -(CRR')p-O-lower alkyl, -(CRR')p-S-lower alkyl, -(CRR') p -O-lower alkyl substituted by hydroxy or C 3-6 -cycloalkyl; R/R' are independently from each other hydrogen, lower alkyl or lower alkyl substituted by hydroxyl; n is 1 or 2; o is 1 or 2; P is 0, 1, 2, 3 or 4; or to pharmaceutically active acid-addition salts thereof.
    • 本发明涉及式(I)的吡咯烷衍生物,其中R 1是氢,卤素或低级烷基; R 2是氢,卤素,低级烷氧基或被卤素取代的低级烷基; R 3是 - 任选被低级烷基,卤素,-S(O)2取代的 - (CH 2)2 - 杂环基) 低级烷基,-C(O) - 低级烷基,-C(O)O-低级烷基,羟基,被羟基取代的低级烷基, - (CH 2) 或低级烷基,-NHCO-低级烷基,或为任选被= O, - (CH 2)2取代的C 3-6环烷基, 低级烷基或低级炔基,或未取代或取代的芳基或杂芳基,其中取代基选自低级烷基,CN,-S(O)2, 低级烷基,卤素,-C(O) - 低级烷基,羟基,低级烷氧基或被卤素取代的低级烷氧基; 或是 - (CH 2)2 - - - - - - - - - - - - - - - R 4和R 5彼此独立地是氢,低级烷基, - 被羟基取代的 - (CRR')对 - 低级烷基, - (CRR')pO-低级 烷基, - (CRR')pS-低级烷基, - (CRR')由羟基或C 3-6 - 环烷基取代的-O-低级烷基; R / R'彼此独立地为氢,被羟基取代的低级烷基或低级烷基; n为1或2; o是1或2; P为0,1,2,3或4; 或其药学活性的酸加成盐。